[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU86703A - Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)-heksadeka-2(11),3,5,7,9-pentaena - Google Patents

Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)-heksadeka-2(11),3,5,7,9-pentaena

Info

Publication number
YU86703A
YU86703A YU86703A YUP86703A YU86703A YU 86703 A YU86703 A YU 86703A YU 86703 A YU86703 A YU 86703A YU P86703 A YUP86703 A YU P86703A YU 86703 A YU86703 A YU 86703A
Authority
YU
Yugoslavia
Prior art keywords
triazatetracyclo
pentaene
hexadeca
pharmaceutical compositions
tartrate salt
Prior art date
Application number
YU86703A
Other languages
English (en)
Inventor
David Everett Bogle
Peter Robert Rose
Glenn Robert Williams
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU86703(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU86703A publication Critical patent/YU86703A/sh
Publication of RS50814B publication Critical patent/RS50814B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Ovaj pronalazak se odnosi na tartaratne soli 5,8,14-triazatetraciklo[10.3.1.02,1104,9]-heksadeka-2(11),3,5,7,9-pentaena (formule 1) i njihove farmaceutske kompozicije. Ovaj pronalazak se posebno odnosi na L-tartaratnu so i dalje na različite polimorfne oblike L-tartaratne soli uključujući dva očigledna anhidrovana polimorfna oblika (ovde označeni kao Oblici A i B) i hidratni polimorfni oblik (ovde označen kao Oblik C). Dodatno, ovaj pronalazak se takođe odnosi na D-tartaratnu so 5,8,14-triazatetraciklo[10.3.1.02,11.O4,9]-heksadeka-2(11),3,5,7,9-pentaena i njegove različite polimorfne oblike; kao i na njegovu D,L-tartaratnu so i njegove polimorfne oblike i na njegovu mezo-tartaratnu so i njene polimorfne oblike.[The present invetion is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene of formula (1), and pharmaceutical compositions thereof. The present invetion in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polmorph (referred to hrein as Form C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and the various polmorphs tereof; as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs.
YUP-867/03A 2001-05-14 2002-04-26 Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena RS50814B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086101P 2001-05-14 2001-05-14

Publications (2)

Publication Number Publication Date
YU86703A true YU86703A (sh) 2006-05-25
RS50814B RS50814B (sr) 2010-08-31

Family

ID=23117845

Country Status (48)

Country Link
US (2) US6890927B2 (sh)
EP (1) EP1392307B1 (sh)
JP (1) JP3779682B2 (sh)
KR (1) KR100551184B1 (sh)
CN (1) CN100370987C (sh)
AP (1) AP1473A (sh)
AR (1) AR033635A1 (sh)
AT (1) ATE302607T1 (sh)
AU (1) AU2002253482B2 (sh)
BG (1) BG66408B1 (sh)
BR (1) BR0209605A (sh)
CA (1) CA2447405C (sh)
CR (1) CR7080A (sh)
CZ (1) CZ304763B6 (sh)
DE (1) DE60205742T2 (sh)
DK (1) DK1392307T3 (sh)
DO (1) DOP2002000392A (sh)
EA (1) EA005528B1 (sh)
EC (2) ECSP034849A (sh)
EE (1) EE05441B1 (sh)
EG (1) EG24228A (sh)
ES (1) ES2246396T3 (sh)
GE (1) GEP20053712B (sh)
GT (1) GT200200084A (sh)
HK (1) HK1062645A1 (sh)
HR (1) HRP20030910B1 (sh)
HU (1) HU229867B1 (sh)
IL (2) IL157933A0 (sh)
IS (1) IS2217B (sh)
MA (1) MA27020A1 (sh)
ME (1) ME00466B (sh)
MX (1) MXPA03010364A (sh)
MY (1) MY127807A (sh)
NO (1) NO326148B1 (sh)
NZ (1) NZ528210A (sh)
OA (1) OA12599A (sh)
PA (1) PA8545101A1 (sh)
PE (1) PE20021065A1 (sh)
PL (1) PL214876B1 (sh)
PT (1) PT1392307E (sh)
RS (1) RS50814B (sh)
SI (1) SI1392307T1 (sh)
SK (1) SK287170B6 (sh)
TN (1) TNSN03113A1 (sh)
TW (1) TWI262078B (sh)
UA (1) UA73422C2 (sh)
WO (1) WO2002092089A1 (sh)
ZA (1) ZA200307235B (sh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504482A (en) * 1997-12-31 2003-01-31 Pfizer Prod Inc Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
EP1448235B1 (en) * 2001-11-30 2007-03-14 Pfizer Products Inc. Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
MXPA05012507A (es) * 2003-05-20 2006-01-30 Pfizer Prod Inc Composiciones farmaceuticas de vareniclina.
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
EA010307B1 (ru) * 2004-06-30 2008-08-29 Эли Лилли Энд Компани Фармацевтическое соединение
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006040680A1 (en) * 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
AU2006217616A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Preparation of high purity substituted quinoxaline
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
AU2007319951A1 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
EP2262780A4 (en) * 2008-03-06 2012-01-25 Reddys Lab Ltd Dr TARTRATE OF VARENICLINE AMORPHOUS
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2440187A2 (en) 2009-06-10 2012-04-18 Actavis Group PTC ehf. Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
CA2791460A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US9090623B2 (en) 2012-04-13 2015-07-28 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Compound JK12A and preparation thereof
KR101663550B1 (ko) * 2014-06-11 2016-10-07 조선대학교산학협력단 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
KR20240038022A (ko) 2021-08-20 2024-03-22 비위트 파마슈티컬 컴퍼니 리미티드 니트로사민 불순물, 니트로사민 불순물 생성을 줄일 수 있는 바레니클린 약학 조성물 및 그 제조와 응용
KR20230068877A (ko) 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) * 2021-11-22 2023-05-09 浙江车头制药股份有限公司 一种酒石酸伐尼克兰晶型的制备方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines
KR20240115109A (ko) 2023-01-18 2024-07-25 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물
WO2024224270A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Varenicline formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
NZ504482A (en) * 1997-12-31 2003-01-31 Pfizer Prod Inc Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic

Also Published As

Publication number Publication date
TWI262078B (en) 2006-09-21
DK1392307T3 (da) 2005-11-07
JP3779682B2 (ja) 2006-05-31
NO326148B1 (no) 2008-10-06
DE60205742D1 (de) 2005-09-29
BG108343A (bg) 2004-12-30
SK287170B6 (sk) 2010-02-08
GT200200084A (es) 2003-09-12
EE200300556A (et) 2004-04-15
MY127807A (en) 2006-12-29
NO20035036D0 (no) 2003-11-13
HUP0304088A2 (hu) 2004-04-28
NO20035036L (no) 2003-11-13
CA2447405A1 (en) 2002-11-21
HRP20030910B1 (en) 2011-11-30
EP1392307A1 (en) 2004-03-03
GEP20053712B (en) 2005-12-26
IL157933A0 (en) 2004-03-28
CA2447405C (en) 2006-10-17
JP2004533446A (ja) 2004-11-04
EA005528B1 (ru) 2005-04-28
US20050148591A1 (en) 2005-07-07
HUP0304088A3 (en) 2011-11-28
PE20021065A1 (es) 2002-11-21
KR100551184B1 (ko) 2006-02-13
PL214876B1 (pl) 2013-09-30
KR20040010638A (ko) 2004-01-31
BG66408B1 (bg) 2014-01-31
EA200301121A1 (ru) 2004-02-26
DE60205742T2 (de) 2006-05-11
PT1392307E (pt) 2005-11-30
NZ528210A (en) 2005-04-29
SK13362003A3 (en) 2004-11-03
CN1509174A (zh) 2004-06-30
EG24228A (en) 2008-11-10
PA8545101A1 (es) 2003-09-05
HU229867B1 (en) 2014-10-28
ZA200307235B (en) 2004-09-16
IS6957A (is) 2003-09-15
TNSN03113A1 (fr) 2005-12-23
ECSP034850A (es) 2003-12-24
DOP2002000392A (es) 2002-11-15
CZ304763B6 (cs) 2014-10-01
CN100370987C (zh) 2008-02-27
US7265119B2 (en) 2007-09-04
AP2002002523A0 (en) 2002-06-30
AU2002253482B2 (en) 2007-09-06
BR0209605A (pt) 2004-03-23
MXPA03010364A (es) 2004-03-16
PL366551A1 (en) 2005-02-07
ECSP034849A (es) 2003-12-24
UA73422C2 (en) 2005-07-15
WO2002092089A1 (en) 2002-11-21
ME00466B (me) 2011-10-10
AP1473A (en) 2005-09-30
MA27020A1 (fr) 2004-12-20
SI1392307T1 (sl) 2005-12-31
US20030166701A1 (en) 2003-09-04
ES2246396T3 (es) 2006-02-16
CZ20032916A3 (cs) 2004-09-15
HRP20030910A2 (en) 2004-02-29
US6890927B2 (en) 2005-05-10
EP1392307B1 (en) 2005-08-24
OA12599A (en) 2006-06-08
AR033635A1 (es) 2003-12-26
RS50814B (sr) 2010-08-31
EE05441B1 (et) 2011-08-15
ATE302607T1 (de) 2005-09-15
IS2217B (is) 2007-03-15
HK1062645A1 (en) 2004-11-19
CR7080A (es) 2006-08-09
IL157933A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
YU86703A (sh) Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)-heksadeka-2(11),3,5,7,9-pentaena
WO2006077025A3 (en) Morpholines as 5ht2c agonists
GB0114286D0 (en) Nucleoside Derivatives
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MXPA03010365A (es) Sal citrato de 5,7,14-triazatetraciclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma.
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
MY151295A (en) Pyrimidyl indoline compound
HK1113086A1 (en) Pharmaceutical formulation of apomorphine for buccal administration
MXPA04008152A (es) Compuestos azabiciclicos para el tratamiento de enfermedades.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MX2010014230A (es) Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
HU0301173D0 (en) Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
RS20050954A (en) Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
MY134325A (en) Quinoline derivatives
IL157241A0 (en) Malic acid addition salts of terbinafine
NZ584037A (en) Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
TW200612941A (en) Quinorone-containing pharmaceutical composition
SI1915375T1 (sl) Derivati 5-piridinil-1-azabiciklo(3.2.1)oktana, njihova priprava in njihova terapevtska uporaba
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
MXPA04000952A (es) Sales de derivados de acido 1,2,3-4-tetrahidro-isoquinolin-2-carboxilico.